Participation in social activities, sports and other hobbies is also negatively affected. 4 For many patients quality of life (QoL) is reduced for one to two weeks following surgery. 5 Postoperative complications may include swelling, bruising and limited mouth opening along with difficulty with eating, which can be a major concern to patients and has not been appreciated by healthcare professionals in the past. 6 However, patients are often most concerned about postoperative pain, which may be severe. Approximately one in two patients will experience pain despite analgesic therapy, even one week after surgery. 5 The pain experienced after oral surgery is a validated and widely used pain model for the clinical evaluation of analgesic efficacy. 7 Paracetamol (acetaminophen) and ibuprofen are commonly prescribed analgesics used extensively in the management of postoperative third molar pain. 8, 9 In 2010, a novel drug marketed as Nuromol was introduced in the UK, 10 this single tablet includes both paracetamol and ibuprofen. Early trials have shown encouraging data on its analgesic efficacy,
INTRODUCTION
This article is based on the Cochrane review Ibuprofen and/or paracetamol (acetaminophen) for pain relief after surgical removal of lower wisdom teeth 1 published in the Cochrane Database of Systematic Reviews (CDSR) 2013. Cochrane reviews are regularly updated as new evidence emerges and in response to feedback, and the CDSR should be consulted for the most recent version of the review.
BACKGROUND
The removal of wisdom teeth is an extremely common surgical procedure with hospital episode statistics estimating that 77,000 patients underwent such a procedure during the year 2009/10. 2 Research suggests that wisdom tooth removal has an immediate negative impact on patients' working and social lives: in one study patients took an average of 1.6 days off work, with over one third of patients stating that the surgery This paper compares the beneficial and harmful effects of paracetamol, ibuprofen and the novel combination of both in a single tablet for pain relief following the surgical removal of lower wisdom teeth. In this systematic review only randomised controlled double-blinded clinical trials were included. We calculated the proportion of patients with at least 50% pain relief at 2 and 6 hours post dosing, along with the proportion of participants using rescue medication at 6 and 8 hours. Adverse events were also analysed. Data was meta-analysed where possible. Seven studies were included with a total of 2,241 participants enrolled. Ibuprofen 400 mg is superior to 1,000 mg paracetamol with a risk ratio for at least 50% pain relief at 6 hours of 1.47 (95% confidence interval [CI] 1.28 to 1.69). For the combined drug, the risk ratio for at least 50% maximum pain relief over 6 hours is 1.77 (95% CI 1.32 to 2.39) based on total pain relief (TOTPAR) data. There is high quality evidence that ibuprofen is superior to paracetamol. The novel combination drug shows encouraging results when compared to the single drugs (based on two trials).
and safety of ibuprofen and paracetamol individually, without direct comparison, for postoperative pain management. These reviews have included the findings of studies involving a wide variety of types of surgery such as inguinal hernia surgery, caesarean section, orthopaedic surgery and the removal of wisdom teeth. Only one review to date looks at paracetamol specifically in relation to postoperative third molar removal pain, 15 although two other reviews of single dose postoperative analgesics include subgroup analyses for dental pain only. 13, 16 There is some debate as to whether dental pain is different from other pain. It has been suggested that the effect of certain analgesics including tramadol is worse for dental pain than for other types of postsurgical pain.
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OBJECTIVES
In this review we investigated the optimal dose of ibuprofen versus paracetamol by direct comparison, taking into account the side effects of different doses of the drugs. This would inform dentists, oral surgeons and their patients of the optimal strategy for best pain relief when considering ibuprofen or paracetamol (or a combination of both) following the surgical removal of wisdom teeth.
• Provides a summary of the best current evidence on the efficacy of paracetamol and ibuprofen using the third molar pain model.
• Compares the analgesic capabilities of the two agents.
• Considers the evidence for using a single drug that contains both active analgesics.
• Précises the findings from this review in light of other Cochrane reviews in the field.
I N B R I E F
PRACTICE
This review was completed according to the Cochrane handbook for systematic reviews of interventions. 18 More information on the work of the Oral Health Group is available online.
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SUBJECTS AND METHODS
All included studies were randomised controlled double-blinded clinical trials. Crossover studies were included provided there was a wash out period of at least 14 days.
Participants
Patients of all health states without intolerances/ allergies to the study drugs who required the surgical removal of a lower wisdom tooth or teeth that required bone removal or at least registering a baseline pain intensity of moderate to severe pain. Patients who required removal of an additional tooth or teeth were also included. Surgery was undertaken under local anaesthesia, intravenous sedation or general anaesthesia. Patients taking concurrent analgesia were excluded.
Interventions
Ibuprofen, paracetamol or a combination of both given as a single dose postoperatively by mouth in any dose and in any formulation (for example, immediate or slow release).
Searching
We searched the following electronic databases: Two review authors independently and in duplicate scanned the titles and abstracts (when available) of all reports identified. Data was extracted using specially designed data extraction forms. Any disagreement was discussed and a third review author consulted where necessary. Authors were contacted for clarification of missing information. Data were excluded until further clarification was available if agreement was not reached.
OUTCOME MEASURES
Pain relief
Authors commonly report on the results of analgesic trials using mean data with associated standard deviations, this is a problem as the data may be asymmetrically distributed and if used in meta-analyses will lead to potentially erroneous conclusions. 20 It is therefore important to derive dichotomous data from the continuous data presented in trials before using the data in meta-analyses. The team at the Oxford Pain Relief Unit and Nuffield Department of Anaesthetics have derived a method for dichotomising this data; the detailed background and verification were published over three papers in the late 1990s. [20] [21] [22] From the data presented in the trials, the proportion of patients achieving 50% pain relief (50% maximum total pain relief [TOTPAR])) was calculated and used in the meta-analysis. Other Cochrane reviews have made use of these measures in their analyses. [13] [14] [15] Summed pain intensity difference (SPID) essentially measures the same outcome as TOTPAR. If data were unavailable to calculate TOTPAR, SPID would have been calculated. If data on both TOTPAR and SPID were available, TOTPAR was chosen in preference. Outcomes were assessed for 2 hours and 6 hours post-dosing (where possible). For these dichotomous outcomes, the estimate of an intervention was expressed as risk ratios together with 95% confidence intervals. 
Use of rescue medication
Data on the percentage of patients taking rescue medication over the study period were also included in a separate meta-analysis.
RESULTS
Seven studies were included in this review. 10, 11, [23] [24] [25] [26] [27] They contained data on 2,241 participants. All of these studies included a direct comparison of ibuprofen to paracetamol or the combination of both agents in the same drug. The majority of the trials (six) were conducted in the USA, with one trial conducted in Puerto Rico. 27 Four of the trials were completed in clinical research facilities, 10, 11, 23, 26 two in university dental hospitals 25, 27 and one in a private oral surgery clinic. 24 
Characteristics of the participants
The participants were broadly similar in the included trials; all contained the following exclusion criteria: ).
Age ranges were broadly similar with 16-40 years accounting for the vast majority of participants.
Characteristics of the interventions
See Table 1 for a summary of the doses used in the included studies.
Type of anaesthetic used
In two studies, general anaesthetic with supplemental local anaesthetic was used. 24, 26 Local anaesthetic alone was used in one study. 27 Local anaesthetic with supplemental sedation was used in four studies, one using inhalation sedation with nitrous oxides, 23 two with nitrous oxide, diazepam and a barbituate, 10, 11 and in one study 'most patients' received intravenous conscious sedation. 25 
Number of doses of analgesic given
For the purposes of data extraction in this review, only the data from the first postoperative dose were used. The patients were monitored for between 6 and 8 hours from this first dose before re-medication.
Risk of bias in included studies
Risk of bias was assessed using the five domains as described in Table 2 . Figure 1 provides a summary of the risk of bias judgement in the included studies. 'A bias is a systematic error, or deviation from the truth, in results or inferences' . 18 Bias in clinical trials can lead to underestimation or overestimation of the true effect of an intervention.
Comparison one: ibuprofen versus paracetamol
The most relevant comparison was between ibuprofen given as a 400 mg dose and paracetamol given as a 1,000 mg dose as these are the most commonly prescribed doses in clinical practice.
Outcome TOTPAR -greater than 50% pain relief over 6 hours
The overall risk ratio was 1.47 (95% CI 1.28 to 1.69; p <0.00001), indicating that 47% more patients achieved at least 50% of the maximum pain relief over 6 hours in the ibuprofen group.
Outcome TOTPAR -greater than 50% pain relief over 2 hours
The overall risk ratio was 1.30 (95% CI 1.09 to 1.55; p <0.00001), indicating that 30% more patients achieved at least 50% of the maximum pain relief over 2 hours in the ibuprofen group compared to the paracetamol group.
See Table 3 for analysis of this comparison.
Comparison two: combined (ibuprofen and paracetamol) versus single drugs
The two outcomes for TOTPAR were only based on data from one trial, 10 therefore they *The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio; OR: odds ratio. GRADE Working Group grades of evidence -High quality: further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: we are very uncertain about the estimate.
This is the median control group risk based on paracetamol being the control group.
cannot be considered as meta-analyses. All of the comparisons were between paracetamol 1,000 mg and ibuprofen 400 mg in the same tablet, and the same constituent drugs given as single tablets. It was not possible to derive TOTPAR and/or SPID data as the trial 11 used a two-stage design; despite contact with the authors, we did not obtain the specific data required to dichotomise the trial results for meta-analysis.
Outcome TOTPAR -greater than 50% pain relief over 6 hours
This comparison demonstrates a risk ratio of 1.77 (95% CI 1.32 to 2.39; p = 0.0002), indicating that 77% more patients achieved at least 50% of the maximum pain relief over 6 hours in the combined drug group as did in the single drug group.
Outcome TOTPAR -greater than 50% pain relief over 2 hours
This outcome demonstrates a risk ratio of 1.29 (95% CI 0.91 to 1.85; p = 0.15), indicating that 29% more patients achieved at least 50% of the maximum pain relief over 2 hours in the combined drug group as did in the single drug group.
Number of patients using rescue medication at 8 hours
The results of two studies were included in this analysis, 10, 11 which compared the efficacy of a combination of paracetamol 1,000 mg/500 mg with ibuprofen 400 mg/200 mg in the same pill with the individual constituent drugs taken together. The lower dose was included here in order to perform a meta-analysis of single vs combined drugs. There was no difference between the subgroups (p = 0.39), and the overall risk ratio was 1.67 (95% CI 1.48 to 1.90; p <0.00001) indicating that 67% fewer patients used rescue medication over Table 4 and Figure 2 for further details.
Summary of findings
Using the software GRADE profiler 3.6, the quality of the body of evidence was assessed for both comparisons: ibuprofen versus paracetamol, and combined (ibuprofen and paracetamol) versus single drugs. TOTPAR and use of rescue medication were assessed as SPID is measuring the same outcome as TOTPAR. A summary of findings for the two comparisons is shown in Table 3 and Table 4 . These tables show that all of the outcomes for comparing ibuprofen versus paracetamol were found to be of quality. The comparisons for combined (ibuprofen and paracetamol) versus single drugs for TOTPAR are both of moderate quality as they were downgraded due to being based on data from single studies and the imprecision of estimate. The evidence for use of rescue medication was assessed as high quality.
CONCLUSIONS
There is high quality evidence that ibuprofen is superior to paracetamol at doses of 400 mg ibuprofen and 1,000 mg paracetamol; these are the most frequently used doses in clinical practice. This review proves ibuprofen to be superior to paracetamol in terms of analgesic efficacy when used postoperatively for pain management following the surgical removal of lower wisdom teeth. It is important to be aware that the data in this review only relate to single dose postoperative usage of the trial drugs. The combined drugs containing both agents show promising outcomes, with metaanalysis of the use of rescue medication at 8 hours providing high quality evidence that the combined drugs are superior to the single drugs. This finding is echoed by a recent Cochrane review that found that participants had a smaller chance of requiring rescue medication over 8 hours if they took the combined drug compared to the individual agents. 28 It has been suggested that these findings could be due to the formulation of the combined drug having a faster onset of analgesia. 29 However, we found that at 2 hours postoperatively, there was no significant difference between the paracetamol, ibuprofen and combined drug, implying that the drug had a 'delayed' effect relative to the single drug. That is, at 6 hours the combined drug was more effective. All drugs studied in this review are generally considered safe with minimal side effects noted when used for short-term pain relief. It is important to remember that many patients are able to tolerate paracetamol and ibuprofen, and on the basis of evidence in this review prescribing both analgesics either as individual tablets or in combination would take advantage of their differing pharmacological properties and achieve adequate pain relief for patients following the surgical removal of lower third molar teeth.
